Company news
Biohaven Ltd. (NYSE:BHVN) news
Biohaven Ltd. news releases on 6ix. Latest, Sep 28, 2026: Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I…
Press releases & updates
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
September 28, 2026
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
August 27, 2026
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
July 20, 2026
Biohaven Announces Scientific Leadership Transitions
July 9, 2026
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
June 30, 2026
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
June 29, 2026
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
June 1, 2026
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
May 26, 2026
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
May 4, 2026
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
March 19, 2026
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
March 2, 2026
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
January 7, 2026
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder
December 24, 2025
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
December 11, 2025
Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M
November 13, 2025
Biohaven Announces Pricing of $175 Million Public Offering of Common Shares
November 12, 2025
Biohaven Announces Proposed Public Offering of Common Shares
November 11, 2025
Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments
November 10, 2025
FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia
November 4, 2025
Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments
August 11, 2025
Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development
June 10, 2025
Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor
May 29, 2025
Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN)
May 28, 2025
Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors
May 28, 2025
FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia
May 14, 2025
Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments
May 12, 2025
Biohaven Announces Investment up to $600 Million by Oberland Capital
April 28, 2025
Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting
April 5, 2025
Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
March 3, 2025
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results
March 3, 2025
Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia
February 12, 2025
Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 8, 2025
Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested, Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates
December 17, 2024
Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting
December 9, 2024
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity
November 26, 2024
Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments
November 13, 2024
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares
October 3, 2024
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares
October 2, 2024
Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia
September 23, 2024